emily_PDX — wow. I've been looking for this exact info for weeks.

Slightly tangential to MASH prevalence in GLP-1 but tampaLisa73 reminded me — has anyone else noticed changes in their alcohol tolerance?

I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.

Thanks for sharing this, tampaLisa73. A few questions about your MASH prevalence in experience:

1. What dose did you start at?
2. How long before you noticed side effects improving?
3. Did your provider have any specific recommendations about MASH prevalence?

I am in a similar boat and trying to learn from others' experiences before my next appointment.

OP here — wow, did not expect this much response! Thank you all for the thoughtful replies on MASH prevalence in GLP-1.

To answer bri_stats: I get my labs done through Quest every 3 months.

Quick update: my latest labs came back even better. Thanks again for the evidence-based discussion — this is exactly why I posted in a science-based community. 🙏

Relevant to MASH prevalence in GLP-1 users — here is my latest bloodwork comparison:

Key improvements: A1C 8.0% → 5.3%, triglycerides 199 → 99 mg/dL, hsCRP 6.0 → 1.1 mg/L. All on tirzepatide for 15 months.

The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.